Related Experiment Video

Updated: Aug 25, 2025

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.4K

Targeting α7 nicotinic acetylcholine receptors for chronic pain

Ya-Qun Zhou1, Dai-Qiang Liu1, Cheng Liu1

  • 1Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Frontiers in Molecular Neuroscience
|October 17, 2022
PubMed

Insights

Targeting alpha7 nicotinic acetylcholine receptors (α7 nAChR) shows promise for chronic pain relief. Potentiating these receptors, particularly by reducing neuroinflammation, offers a potential new therapeutic avenue beyond traditional opioids.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pain Research

Background:

  • Chronic pain management remains challenging, with opioids often causing adverse effects.
  • Opioid-based pain relief strategies have seen limited improvement over decades.
  • Understanding chronic pain mechanisms is crucial for developing novel therapeutics.

Purpose of the Study:

  • To review preclinical evidence for alpha7 nicotinic acetylcholine receptors (α7 nAChR) as a therapeutic target for chronic pain.
  • To discuss the potential of α7 nAChR agonists and allosteric modulators in pain management.
  • To highlight the role of α7 nAChR potentiation in alleviating chronic pain behaviors.

Main Methods:

  • Review of preclinical studies and rodent models of chronic pain.
  • Analysis of evidence for α7 nAChR downregulation in pain pathways.
  • Examination of studies demonstrating pain attenuation through α7 nAChR potentiation.

Main Results:

  • Downregulation of α7 nAChR is observed in key nervous system regions in chronic pain models.
  • Potentiation of α7 nAChR has been shown to reduce pain behaviors in various animal models.
  • Alleviation of neuroinflammation is a primary mechanism by which α7 nAChR activation benefits chronic pain.

Conclusions:

  • α7 nAChR potentiation demonstrates significant therapeutic potential for chronic pain.
  • Targeting α7 nAChR offers a promising alternative to current pain management strategies.
  • Further research into the detailed mechanisms of α7 nAChR in chronic pain is warranted.
Keywords:
chronic painmicroglianeuroinflammationoxidative stressα7 nAChR

More Related Videos

Intracranial Pharmacotherapy and Pain Assays in Rodents02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.3K
Development of Recombinant Proteins to Treat Chronic Pain10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.6K

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
761
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
833
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.6K
Cholinergic Receptors: Nicotinic01:15

Cholinergic Receptors: Nicotinic

Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
3.2K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.5K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
1.2K